Diagnosis and treatment of amyotrophic lateral sclerosis according to EFNS recommendations (2005);Rozpoznawanie i leczenie stwardnienia bocznego zanikowego zgodnie z zaleceniami Europejskiej Federacji Towarzystw Neurologicznych (EFNS) z 2005 r

Neurologia i Neurochirurgia Polska

Volumn 41, Issue 5, 2007, Pages 445-456

  Tomik, Barbara ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

ALS; Diagnosis; EFNS; Treatment

Indexed keywords

ACETYLCYSTEINE; AMITRIPTYLINE; ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; DEXTROMETHORPHAN; DIAZEPAM; FLUVOXAMINE; FUROSEMIDE; LORAZEPAM; SCOPOLAMINE;

AMYOTROPHIC LATERAL SCLEROSIS; DIET THERAPY; GASTROSTOMY; HUMAN; INTERPERSONAL COMMUNICATION; NEUROPROTECTION; PALLIATIVE THERAPY; QUALITY OF LIFE; REHABILITATION CARE; REVIEW; SYSTEMIC THERAPY; TEAMWORK;

AMYOTROPHIC LATERAL SCLEROSIS; HUMANS; PALLIATIVE CARE; PATIENT CARE TEAM; QUALITY OF LIFE;

EID: 36749064866     PISSN: 00283843     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Miller R.G, Rosenberg J.A., Gelinas D.F. i wsp. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. ALS Practice Parameters Task Force. Neurology 1999; 52: 1311-1323.
2. Andersen P.M., Borasio G.D., Dengler R. i wsp. EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. Eur J Neurol 2005; 12: 921-938.
3. Brainin M., Barnes M., Baron J.C. i wsp. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2004. Eur J Neurol 2004; 11: 577-581.
4. National Institute for Clinical Excellence. Guidance on the use of Riluzole (Rilutek) for the treatment of motor neurone disease. TA20, 19 January 2001. Adres: www.nice.org.uk/ search.aspx?searchmode=simple&ss=ALS.
5. Sykes N., Thorns A. The use of opioids and sedatives at the end of life. Lancet Oncol 2003; 4: 312-318.
6. Kwieciński H. Symptomatic treatment and palliative care of ALS. Neurol Neurochir Pol 2001; 35 (supl. 1): 51-59.
7. Tomik B. Zasady postepowania w SLA. W: Banach M., Bogucki A., Liberski P [red.]. Choroby rdzenia kregowego. Wyd. 1. Medycyna Praktyczna, Kraków 2006, ss. 153-161.
8. Kwieciński H. [red.]. Stwardnienie boczne zanikowe. Medycyna Praktyczna, Kraków 2007.
9. Lacomblez L., Bensimon G., Leigh P.N. i wsp. ALS Study Groups I and II. Long-term safety of riluzole in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002; 3: 23-29.
10. Miller R.G., Mitchell J.D., Lyon M. i wsp. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007; CD001447.
11. Desport J.C., Preux P.M., Truong C.T. i wsp. Nutritional assessment and survival in ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 91-96.
12. Mathus-Vliegen L.M., Louwerse L.S., Merkus M.P. i wsp. Percutaneous endoscopic gastrostomy in patients with amyotrophic lateral sclerosis and impaired pulmonary function. Gastrointest Endosc 1994; 40: 463-469.
13. Leigh P.N., Abrahams S., Al-Chalabi A. i wsp. The Management of motor neurone disease. J Neurol Neurosurg Psychiatry 2003; 70 (Suppl IV): iv32-iv47.
14. Heffernan C., Jenkinson C., Holmes T. i wsp. Nutritional management in MND/ALS patients: an evidence based review. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 72-83.
15. Chio A., Mora G., Balzarino C. i wsp. Interdisciplinary ALS Centres: Effect of survival and use of health services in a population-based survey. Neurology 2004; 62 (Supl. 5): S23.003.
16. Chio A., Galletti R., Finocchiaro C. i wsp. Percutaneous radiological gastrostomy: a safe and effective method of nutritional tube placement in advanced ALS. J Neurol Neurosurg Psychiatry 2004; 75: 645-647.
17. Traynor B.J., Alexander M., Corr B. i wsp. Effects of a multidisciplinary ALS clinic on survival. J Neurol Neurosurg Psychiatry 2003; 74: 1258-1261.
18. Bourke S.C., Bullock R.E., Williams T.L. i wsp. Noninvasive ventilation in ALS: indications and effect on the quality of life. Neurology 2003; 61: 171-177.
19. Bourke S.C., Gibson G.J. Non-invasive ventilation in ALS: current practice and future role. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 67-71.
20. Drory V.W., Goltsman E., Renik J.G. i wsp. The value of muscle exercise in patients with amyotrophic lateral sclerosis. J Neurol Sci 2001; 191: 133-137.
21. Oliver D., Chan C.W., Sinaki M. Rehabilitation management of the ALS patient. W: Belsh J.M., Schiffman P.L. [red.]. Amyotrophic lateral sclerosis: diagnosis and management for the clinicians. Armonk, Futura Publishing, New York 1996, ss. 315-331.
22. Mitsumoto H., Chad D.A., Pioro E.P. Physical rehabilitation. W: Mitsumoto H., Chad D.A., Pioro E.P. [red.]. Amyotrophic lateral sclerosis. F.A. Davis Company, Philadelphia 1998, ss. 360-381.
23. Ball L.J., Beukelman D.R., Pattee G.L. Communication effectiveness of individuals with amyotrophic lateral sclerosis. J Commun Disord 2004; 37: 197-215.
24. Murphy J. Communication strategies of people with ALS and their partners. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 121-126.
25. Adres: http://www.alsod.org/
26. Andersen P.M., Sims K.B., Xin W.W. i wsp. Sixteen novel mutations in the gene encoding CuZn-superoxide dismutase in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 2: 62-73.
27. Andersen P.M., Spitsyn V.A., Makarov S.V. i wsp. The geographical and ethnic distribution of the D90A CuZn-SOD mutation in the Russian Federation. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2: 63-69.
28. Jonsson P.A., Backstrand A., Andersen P.M. i wsp. CuZn-superoxide dismutase in D90A heterozygotes from recessive and dominant ALS pedigrees. Neurobiol Dis 2002; 10: 327-333.
29. Andersen P.M., Nilsson P., Keränen M.L. i wsp. Phenotypic heterogeneity in MND-patients with CuZn-superoxide dismutase mutations in Scandinavia. Brain 1997; 120: 1723-1737.
30. Jones C.T., Swingler R.J., Simpson S.A. i wsp. Superoxide dismutase mutations in an unselected cohort of Scottish amyotrophic lateral sclerosis patients. J Med Genet 1995; 32: 290-292.
31. Andersen P.M., Forsgren L., Binzer M. i wsp. Autosomal recessive adult-onset ALS associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Brain 1996; 119: 1153-1172.
32. Gasser T., Dichgans M., Finsterer J. i wsp. EFNS task force on molecular diagnosis of neurologic disorders. Part 1. Eur J Neurol 2001; 8: 299-314.
33. Andersen P.M., Borasio G.D., Dengler R. i wsp. Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence-based review with good practice points. EALSC Working Group. Amyotroph Lateral Scler 2007; 8: 195-213.
34. Bourke S.C., Tomlinson M., Williams T.L. i wsp. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 2006; 5: 140-147.
35. Gruis K.L., Brown D.L., Weatherwax K.J. i wsp. Evaluation of sham non-invasive ventilation for randomized, controlled trials in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2006; 7: 96-99.
36. Heffernan C., Jenkinson C., Holmes T. i wsp. Management of respiration in MND/ALS patients: an evidence based review. Amyotroph Lateral Scler Other Motor Neuron Disord 2006; 7: 5-15.
37. Heiman-Patterson T.D., Miller R.G. NIPPV: a treatment for ALS whose time has come. Neurology 2006; 67: 736-737.
38. Hill N.S. Neuromuscular disease in respiratory and critical care medicine. Respir Care 2006; 51: 1065-1071.
39. Hirano Y.M., Yamazaki Y., Shimizu J. i wsp. Ventilator dependence and expressions of need: a study of patients with amyotrophic lateral sclerosis in Japan. Soc Sci Med 2006; 62: 1403-1413.
40. Jackson C.E., Lovitt S., Gowda N. i wsp. Factors correlated with NPPV use in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2006; 7: 80-85.
41. Lechtzin N. How beneficial is noninvasive ventilation in patients with amyotrophic lateral sclerosis? Nat Clin Pract Neurol 2006; 2: 356-357.
42. Lechtzin N., Lange D.J., Davey C. i wsp. Measures of dyspnea in patients with amyotrophic lateral sclerosis. Muscle Nerve 2007; 35: 98-102.
43. Lepore AC, Maragakis NJ. Targeted stem cell transplantation strategies in ALS. Neurochem Int 2007; 50: 966-975.
44. Lo Coco D., Marchese S., Corrao S. i wsp. Development of chronic hypoventilation in amyotrophic lateral sclerosis patients. Respir Med 2006; 100: 1028-1036.
45. Servera E., Sancho J. Non-invasive ventilation in amyotrophic lateral sclerosis. Lancet Neurol 2006; 5: 291-292.
46. Langmore S., Kasarskis E., Manca M. i wsp. Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2006; CD004030.
47. Shaw A.S., Ampong M.A., Rio A. i wsp. Survival of patients with ALS following institution of enteral feeding is related to pre-procedure oximetry: a retrospective review of 98 patients in a single centre. Amyotroph Lateral Scler Other Motor Neuron Disord 2006; 7: 16-21.
48. Crow J.P. Catalytic antioxidants to treat amyotropic lateral sclerosis. Expert Opin Investig Drugs 2006; 15: 1383-1393.
49. Ashworth N.L., Satkunam L.E., Deforge D. Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2006; CD004156.
50. Czaplinski A., Schweikert K., Strobel W. i wsp. Symptomatic management in amyotrophic lateral sclerosis (ALS). Schweiz Rundsch Med Prax 2006; 95: 263-268, 269-271.
51. De Groot I.J., Post M.W., Van Heuveln T. i wsp. Measurement of decline of functioning in persons with amyotrophic lateral sclerosis: responsiveness and possible applications of the Functional Independence Measure, Barthel Index, Rehabilitation Activities Profile and Frenchay Activities Index. Amyotroph Lateral Scler Other Motor Neuron Disord 2006; 7: 167-172.
52. Neshige R., Murayama N., Tanoue K. i wsp. Optimal methods of stimulus presentation and frequency analysis in P300-based brain-computer interfaces for patients with severe motor impairment. Suppl Clin Neurophysiol 2006; 59: 35-42.
53. Chio A., Bottacchi E., Buffa C. i wsp. Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry 2006; 77: 948-950.
54. Chio A., Gauthier A., Vignola A. i wsp. Caregiver time use in ALS. Neurology 2006; 67: 902-904.